Esperion Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash loss on extinguishment of debt and exchange transaction
Non-cash royalty revenue
Paid-in-kind interest on long-term debt
Non-cash interest expense related to the revenue interest liability
Non-cash interest expense related to the royalty sale liability
Stock-based compensation expense
Depreciation expense
Accretion and amortization of premiums and discounts on investments
Amortization of debt issuance costs and discounts
Acquired in-process research and development
Changes in assets and liabilities:
Accounts receivable
Prepaids and other assets
Deferred revenue
Inventories
Accounts payable
Other accrued liabilities
Other long-term liabilities

Net cash used in operating activities
Investing activities
Purchases of investments
Proceeds from sales/maturities of investments
Purchases of in-process research and development
Purchases of property and equipment
Net cash (used in) provided by investing activities

Financing activities
Proceeds from revenue interest liability, net of issuance costs
Proceeds from royalty sale liability
Payment of royalty sale liability issuance costs
Repurchase or principal payment of revenue interest liability
Payments on revenue interest liability
Payment for debt issuance costs, debt-to-equity conversion
Payment for other issuance costs
Proceeds from credit agreement, net of issuance costs
Proceeds from issuance of convertible notes, net of issuance costs
Repayment of convertible notes
Proceeds from issuance of common stock, net of issuance costs
Proceeds from exercise of common stock options
Proceeds from issuance of common stock from ATM Program, net of issuance costs
Proceeds from exercise of warrants
Proceeds from exercise of pre-funded warrants
Other financing activities
Net cash provided by financing activities

Net increase (decrease) in cash and cash equivalents
Cash, cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Issuance costs not yet paid
Purchase of property and equipment not yet paid
Non-cash right of use asset
Offering costs not yet paid
Income taxes paid (refer to Note 17)
Cash paid for interest

Comments